NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
Filed with ASX · · 2 pages · English
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cynata Receives $1.3m R&D Tax Incentive Refund
- CYP Receives Notice of Allowance from European Patent Office
- September 2018 Quarterly Report
- Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies
- MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
Later from Cynata Therapeutics
- NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis
- Cynata Completes Clinical Study Report in GvHD
- Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD
- CYP Receives Notice of Acceptance from Aust Patent Office
- December 2018 Quarterly Report
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics